Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Treatment for less severe CRS is supportive, addressing the symptoms like fever, muscle pain, or fatigue. Moderate CRS requires oxygen therapy and giving fluids and antihypotensive agents to raise blood pressure. For moderate to severe CRS, the use of immunosuppressive agents like corticosteroids may be necessary, but judgment must be used to ...
Monoclonal antibodies can be acquired in the immune system via passive immunity or active immunity. The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response.
How much does Rituxan cost if you have Medicare Part B? If you have not yet met your 2025 deductible of $257, you will pay that fee. You’ll also be responsible for a 20% coinsurance. Medicare ...
As doctors administer Rituxan as an infusion, Medicare Part B might cover the costs. Learn more about Medicare coverage here.
Necrotizing pneumonia (NP), also known as cavitary pneumonia or cavitatory necrosis, is a rare but severe complication of lung parenchymal infection. [ 1 ] [ 2 ] [ 3 ] In necrotizing pneumonia, there is a substantial liquefaction following death of the lung tissue, which may lead to gangrene formation in the lung.
Hospital acquired pneumonia is the second most common nosocomial infection (after urinary tract infections) and accounts for 15–20% of the total. [1] [2] [3] It is the most common cause of death among nosocomial infections and is the primary cause of death in intensive care units.
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.